Merck's $800 Million Investment In Singapore Aims To Produce Returns Elsewhere
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Merck & Co. Inc. has committed to manufacturing and research investments in Singapore totaling more than $800 million to meet the ever increasing demand in nearby emerging markets
You may also be interested in...
Seeing Is Believing: GSK Pledges To Upgrade Key Antibiotics Plant As Witty Hosts Q3 Call From Singapore
During a celebration to mark GSK’s 40th year in Singapore, CEO Andrew Witty announces new investments in work-horse manufacturing plants and reaffirms openness to share patient data from clinical studies.
An Asia Hub: Novartis Plans Biotech Manufacturing Center In Singapore
Novartis plans to build a new center of excellence for biotechnology manufacturing costing more than $500 million, as it looks to leverage Singapore’s skilled labor force and proximity to growth markets like China.
MerLion Becomes Singapore’s First Biotech To Reach Phase III Trials
The company will pursue a Phase III trial for acute otitis media with a compound that is partnered with Novartis’ Alcon.